<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id><journal-id journal-id-type="hwp">jop</journal-id><journal-title>Journal of Psychopharmacology (Oxford, England)</journal-title><issn pub-type="ppub">0269-8811</issn><publisher><publisher-name>Sage</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18515464</article-id><article-id pub-id-type="pmc">2637477</article-id><article-id pub-id-type="doi">10.1177/0269881108089587</article-id><article-id pub-id-type="publisher-id">08089587</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Papers</subject></subj-group></article-categories><title-group><article-title>Disrupted &#x02018;reflection&#x02019; impulsivity in cannabis                    users but not current or former ecstasy users</article-title><alt-title>Reflection impulsivity in cannabis and ecstasy users</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Clark</surname><given-names>L</given-names></name><xref ref-type="aff" rid="AFF1">1</xref><xref ref-type="aff" rid="AFF2">2</xref></contrib><contrib contrib-type="author"><name><surname>Roiser</surname><given-names>JP</given-names></name><xref ref-type="aff" rid="AFF3">3</xref></contrib><contrib contrib-type="author"><name><surname>Robbins</surname><given-names>TW</given-names></name><xref ref-type="aff" rid="AFF1">1</xref><xref ref-type="aff" rid="AFF2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sahakian</surname><given-names>BJ</given-names></name><xref ref-type="aff" rid="AFF1">1</xref><xref ref-type="aff" rid="AFF4">4</xref></contrib><aff id="AFF1"><label>1</label>Behavioural and Clinical Neuroscience Institute,                    University of Cambridge, Cambridge, UK</aff><aff id="AFF2"><label>2</label>Department of Experimental Psychology, University of                    Cambridge, Cambridge, UK</aff><aff id="AFF3"><label>3</label>Institute of Neurology, Queen Square, London, UK</aff><aff id="AFF4"><label>4</label>Department of Psychiatry, University of Cambridge,                    School of Clinical Medicine, Addenbrooke&#x02019;s Hospital, Cambridge,                UK</aff></contrib-group><author-notes><corresp><italic>Corresponding author:</italic> Dr Luke Clark, Department of                    Experimental Psychology, University of Cambridge, Downing Street, Cambridge CB2                    3EB, UK. Email: <email>lc260@cam.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>1</month><year>2009</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>1</month><year>2009</year></pub-date><volume>23</volume><issue>1</issue><fpage>14</fpage><lpage>22</lpage><permissions><copyright-statement>&#x000a9; 2009 British Association for Psychopharmacology</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><p>This is an open-access article distributed under the terms of the Creative                        Commons Attribution License, which permits unrestricted use, distribution,                        and reproduction in any medium, provided the original work is properly                        cited.</p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="10.1177_0269881108089587.pdf"/><abstract><title>Abstract</title><p>Evidence for serotonin involvement in impulsivity has generated interest in the                    measurement of impulsivity in regular ecstasy users, who are thought to display                    serotonergic dysfunction. However, current findings are inconsistent. Here, we                    used a recently developed Information Sampling Test to measure                    &#x02018;reflection&#x02019; impulsivity in 46 current ecstasy users, 14                    subjects who used ecstasy in the past, 15 current cannabis users and 19                    drug-na&#x000ef;ve controls. Despite elevated scores on the Impulsivity                    subscale of the Eysenck Impulsiveness-Venturesomeness-Empathy questionnaire, the                    current and previous ecstasy users did not differ significantly from the                    drug-naive controls on the Information Sampling Test. In contrast, the cannabis                    users sampled significantly less information on the task, and tolerated a lower                    level of certainty in their decision-making, in comparison to the drug-naive                    controls. The effect in cannabis users extends our earlier observations in                    amphetamine- and opiate-dependent individuals (<xref ref-type="bibr" rid="R6">Clark, <italic>et al</italic>., 2006</xref>, <italic>Biological Psychiatry</italic>                    <bold>60</bold>: 515&#x02013;522), and suggests that reduced reflection may                    be a common cognitive style across regular users of a variety of substances.                    However, the lack of effects in the two ecstasy groups suggests that the                    relationship between serotonin function, ecstasy use and impulsivity is more                    complex.</p></abstract><kwd-group><title>Key words</title><kwd>addiction</kwd><kwd>cannabis</kwd><kwd>decision-making</kwd><kwd>inhibition</kwd><kwd>MDMA</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Impaired inhibitory control in drug addiction is thought to underlie a breakdown of                self-regulation that causes individuals to continue drug administration, despite                growing awareness of the associated negative consequences (<xref ref-type="bibr" rid="R22">Goldstein and Volkow, 2002</xref>; <xref ref-type="bibr" rid="R26">Jentsch and Taylor, 1999</xref>; <xref ref-type="bibr" rid="R31">Lyvers,                2000</xref>). Inhibitory processes can be quantified with neurocognitive measures of                impulsivity, where deficient performance has been demonstrated in regular users of a                wide range of substances, including stimulants, opiates and alcohol (<xref ref-type="bibr" rid="R3">Bjork, <italic>et al</italic>., 2004</xref>; <xref ref-type="bibr" rid="R18">Fillmore and Rush, 2002</xref>; <xref ref-type="bibr" rid="R19">Forman, <italic>et al</italic>., 2004</xref>). Impulsivity has                received particular attention in relation to the regular use of                3,4-methylenedioxymethamphetamine (MDMA) or &#x02018;ecstasy&#x02019;. Studies                of experimental animals have shown that MDMA has selective neurotoxic effects on                serotonin (5-hydroxytryptamine, 5-HT) neurons (<xref ref-type="bibr" rid="R23">Gouzoulis-Mayfrank and Daumann, 2006</xref>), and this serotonin neurotoxicity                may cause or exacerbate impulsivity in human users. There is a longstanding                association between reduced serotonin neurotransmission and behavioural impulsivity                    (<xref ref-type="bibr" rid="R15">Evenden, 1999b</xref>; <xref ref-type="bibr" rid="R47">Soubri&#x000e9;, 1986</xref>), derived from behavioural pharmacology                studies in experimental animals (<xref ref-type="bibr" rid="R51">Tye, <italic>et                    al</italic>., 1977</xref>) and data associating serotonin metabolite and                precursor reductions with clinical impulse control disorders (<xref ref-type="bibr" rid="R28">LeMarquand, <italic>et al</italic>., 1999</xref>; <xref ref-type="bibr" rid="R30">Linnoila, <italic>et al</italic>., 1983</xref>).                Consistent with these data, regular ecstasy users were reported to display impulsive                responding on several laboratory tests, including the Matching Familiar Figures Test                (MFFT) (<xref ref-type="bibr" rid="R37">Morgan, 1998</xref>; <xref ref-type="bibr" rid="R39">Morgan, <italic>et al</italic>., 2002</xref>; <xref ref-type="bibr" rid="R38">Morgan, <italic>et al</italic>., 2006</xref>; <xref ref-type="bibr" rid="R44">Quednow, <italic>et al</italic>., 2007</xref>), the Go/No Go test                    (<xref ref-type="bibr" rid="R36">Moeller, <italic>et al</italic>., 2002b</xref>)                and the Stroop test (<xref ref-type="bibr" rid="R25">Halpern, <italic>et                    al</italic>., 2004</xref>), in comparison to drug-na&#x000ef;ve and                polydrug-using control groups.</p><p>However, the link between impulsivity and ecstasy use remains problematic. Several                case&#x02013;control designs in MDMA users have failed to replicate a basic                deficit on inhibitory measures [Go/No Go (<xref ref-type="bibr" rid="R20">Fox,                        <italic>et al</italic>., 2002</xref>; <xref ref-type="bibr" rid="R24">Gouzoulis-Mayfrank, <italic>et al</italic>., 2003</xref>), Stop Signal Test                    (<xref ref-type="bibr" rid="R52">von Geusau, <italic>et al</italic>.,                2004</xref>), Stroop test (<xref ref-type="bibr" rid="R9">Dafters, 2006</xref>)].                Where positive results have been reported, these effects may be limited to subsets                of ecstasy users [heavy users (<xref ref-type="bibr" rid="R25">Halpern, <italic>et                        al</italic>., 2004</xref>; <xref ref-type="bibr" rid="R36">Moeller,                        <italic>et al</italic>., 2002b</xref>), males (<xref ref-type="bibr" rid="R52">von Geusau, <italic>et al</italic>., 2004</xref>)] or have not reached                statistically significance at conventional thresholds (<xref ref-type="bibr" rid="R44">Quednow, <italic>et al</italic>., 2007</xref>). In addition, the                positive results to date have widely assumed that the impulsivity emerged as a                consequence of ecstasy use via serotonergic neurotoxicity, but have not                satisfactorily excluded the possibility that impulsivity pre-dates drug-taking,                associated with vulnerability mechanisms (<xref ref-type="bibr" rid="R32">Lyvers,                    2006</xref>). At a conceptual level, the 5-HT theory of impulsivity may                represent an over-simplification given evidence from experimental animals that                impulsive responses are negatively related to 5-HT levels in subcortical regions,                but positively related to 5-HT efflux in the prefrontal cortex (<xref ref-type="bibr" rid="R10">Dalley, <italic>et al</italic>., 2002</xref>). These                effects may cancel out following global serotonergic depletion in humans, and we                previously reported no effects of dietary tryptophan depletion on response                inhibition in healthy volunteers (<xref ref-type="bibr" rid="R8">Clark, <italic>et                        al</italic>., 2005</xref>).</p><p>A further problem lies in the measurement of impulsivity, which is increasingly                viewed as a multi-factorial construct (<xref ref-type="bibr" rid="R15">Evenden,                    1999b</xref>; <xref ref-type="bibr" rid="R45">Reynolds, <italic>et al</italic>.,                    2006</xref>). Substance abuse may be differentially associated with various                components of impulsivity. Self-report impulsivity on questionnaire measures is                elevated in substance users of various drugs (<xref ref-type="bibr" rid="R35">Moeller, <italic>et al</italic>., 2002a</xref>; <xref ref-type="bibr" rid="R46">Sher and Trull, 1994</xref>). These groups are also impaired on different                laboratory tests of impulsivity, including delay discounting and response inhibition                    (<xref ref-type="bibr" rid="R1">Bickel and Marsch, 2001</xref>; <xref ref-type="bibr" rid="R3">Bjork, <italic>et al</italic>., 2004</xref>; <xref ref-type="bibr" rid="R18">Fillmore and Rush, 2002</xref>). In the delay                discounting paradigm, impulsivity is defined as preference for immediate small                rewards over larger delayed rewards. On tests of response inhibition, impulsivity is                defined as a failure to suppress automatic or dominant responses. It is striking                that whilst drug users display impairments on each of these measures, these                different aspects of impulsivity are typically only weakly correlated with one                another (<xref ref-type="bibr" rid="R12">Dom, <italic>et al</italic>., 2007</xref>;                    <xref ref-type="bibr" rid="R45">Reynolds, <italic>et al</italic>., 2006</xref>).</p><p>The present report focussed on a further aspect of impulsivity, which has received                less attention in the context of drug use. &#x02018;Reflection&#x02019;                impulsivity refers to the tendency to gather and evaluate information prior to                decision-making, where impulsivity is associated with a failure of reflective                processing. The construct has typically been measured in children using the MFFT                    (<xref ref-type="bibr" rid="R27">Kagan, 1966</xref>), where the subject is                presented with a template picture (e.g. a bicycle) and six similar variants. One                variant is identical to the template, and must be identified on each trial.                Impulsivity is indicated by rapid, inaccurate decisions. Two experiments in ecstasy                users by <xref ref-type="bibr" rid="R37">Morgan (1998)</xref> reported reduced MFFT                accuracy without significant effects on MFFT latency. However, the MFFT places high                demands on visual search, visual working memory and strategy use, and these domains                may be independently disrupted in recreational ecstasy users (<xref ref-type="bibr" rid="R20">Fox, <italic>et al</italic>., 2002</xref>), perhaps leading to                inflated error rates (see <xref ref-type="bibr" rid="R4">Block, <italic>et                    al</italic>. (1974)</xref> and <xref ref-type="bibr" rid="R6">Clark, <italic>et                        al</italic>. (2006)</xref> for further critique of the MFFT).</p><p>In the present study, we have used an alternative measure of reflection impulsivity                that was designed to circumvent several limitations of the MFFT. In the Information                Sampling Test (IST), the subject is presented with a                5&#x000a0;&#x000d7;&#x000a0;5 matrix that conceals boxes that are each one of two                colours (e.g. red or blue). The subject must decide which of the two colours lies in                the majority under the matrix, by uncovering boxes one at a time. Once uncovered,                boxes remain visible for the remainder of the trial such that the working memory                load is negligible. As well as reducing visual search and working memory demand, the                IST also enables the extraction of a direct measure of information sampling (the                probability of being correct at the point of decision) rather than a speed-accuracy                composite as in the MFFT. Critically, the extent of information sampling on the task                is closely correlated with the number of incorrect judgments, meeting a core                criterion for a test of reflection impulsivity (<xref ref-type="bibr" rid="R14">Evenden, 1999a</xref>). We have also shown previously that information sampling                on the IST was associated with slow, accurate responding on the MFFT, providing                evidence for concurrent validity (<xref ref-type="bibr" rid="R7">Clark, <italic>et                        al</italic>., 2003</xref>). Recently, we reported reduced information                sampling in chronic amphetamine and opiate users (<xref ref-type="bibr" rid="R6">Clark, <italic>et al</italic>., 2006</xref>). Whilst healthy controls responded                at 81% certainty (95% confidence intervals: 77&#x02013;85%) when there was no                cost to sampling information, current and former users of amphetamines or opiates                tolerated significantly lower levels of certainty in their decision-making (<xref ref-type="bibr" rid="R6">Clark, <italic>et al</italic>., 2006</xref>). The                present study aimed to extend these data by examining current and former ecstasy                users, as well as drug-na&#x000ef;ve controls, and a fourth group of regular                cannabis users who did not report ecstasy use, as an active control group. We                hypothesized that information sampling would be reduced in the cannabis users, and                that this impulsivity would be further exacerbated in the current and former ecstasy                users as a result of serotonin neurotoxicity.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Subjects</title><p>Participants were 46 current ecstasy users, 14 former ecstasy users, 15 current                    cannabis users and 19 drug-na&#x000ef;ve controls, who were recruited from                    newspaper and magazine advertisements in the Cambridge area. All ecstasy users                    reported a minimum of 30 separate uses of the drug. Current users reported                    abstinence for at least 3&#x000a0;weeks to allow for short-term recovery of                    serotonin function, and the Ex-ecstasy users reported abstinence for at least                    1&#x000a0;year. No participant tested positive for recent stimulant use, as                    assessed by a blood screen. Demographic characteristics are displayed in <xref ref-type="table" rid="tbl1001">Table&#x000a0;1</xref>. All participants                    completed the National Adult Reading Test (NART) (<xref ref-type="bibr" rid="R40">Nelson and Willison, 1991</xref>) as an estimate of verbal IQ, the                    Beck Depression Inventory to record abnormal mood symptoms and the Eysenck                    Impulsiveness-Venturesomeness-Empathy (IVE) questionnaire (<xref ref-type="bibr" rid="R16">Eysenck and Eysenck, 1991</xref>) to measure self-reported                    impulsivity. The protocol was approved by the Cambridge Local Research Ethics                    Committee (LREC number 02/076) and all volunteers provided written informed                    consent prior to participation.</p><table-wrap id="tbl1001" position="float"><label>Table&#x000a0;1</label><caption><p>Demographic and personality variables of the four groups</p></caption><table frame="hsides" rules="groups"><colgroup span="5"><col width="61.25" span="1"/><col width="29.1666666666667" align="char" char="(" span="1"/><col width="29.1666666666667" align="char" char="(" span="1"/><col width="29.1666666666667" align="char" char="(" span="1"/><col width="26.25" align="char" char="(" span="1"/></colgroup><thead><tr><td valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Drug-na&#x000ef;ve</td><td align="left" valign="top" rowspan="1" colspan="1">Ecstasy</td><td align="left" valign="top" rowspan="1" colspan="1">Ex-ecstasy</td><td align="left" valign="top" rowspan="1" colspan="1">Cannabis</td></tr><tr><td colspan="5" rowspan="1"/></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>N</italic></td><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="left" valign="top" rowspan="1" colspan="1">46</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">15</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td valign="top" rowspan="1" colspan="1">24.0 (3.6)</td><td valign="top" rowspan="1" colspan="1">24.2 (6.7)</td><td valign="top" rowspan="1" colspan="1">27.9 (6.6)</td><td valign="top" rowspan="1" colspan="1">22.3 (4.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender (M:F)</td><td align="left" valign="top" rowspan="1" colspan="1">12:7</td><td align="left" valign="top" rowspan="1" colspan="1">33:13</td><td align="left" valign="top" rowspan="1" colspan="1">6:8</td><td align="left" valign="top" rowspan="1" colspan="1">5:10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Verbal IQ</td><td valign="top" rowspan="1" colspan="1">114.6 (4.6)</td><td valign="top" rowspan="1" colspan="1">110.4 (7.6)</td><td valign="top" rowspan="1" colspan="1">110.3 (8.8)</td><td valign="top" rowspan="1" colspan="1">111.3 (9.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BDI</td><td valign="top" rowspan="1" colspan="1">3.5 (2.3)</td><td valign="top" rowspan="1" colspan="1">9.3 (7.6)<sup>a</sup></td><td valign="top" rowspan="1" colspan="1">11.6 (9.2)<sup>a</sup></td><td valign="top" rowspan="1" colspan="1">5.3 (3.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IVE&#x02013;Imp</td><td valign="top" rowspan="1" colspan="1">6.8 (3.9)</td><td valign="top" rowspan="1" colspan="1">10.6 (4.2)<sup>a</sup></td><td valign="top" rowspan="1" colspan="1">11.9 (5.1)<sup>a</sup></td><td valign="top" rowspan="1" colspan="1">8.9 (4.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IVE&#x02013;Vent</td><td valign="top" rowspan="1" colspan="1">10.4 (3.2)</td><td valign="top" rowspan="1" colspan="1">11.0 (3.0)</td><td valign="top" rowspan="1" colspan="1">9.4 (3.9)</td><td valign="top" rowspan="1" colspan="1">10.9 (3.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IVE&#x02013;Emp</td><td valign="top" rowspan="1" colspan="1">12.0 (2.7)</td><td valign="top" rowspan="1" colspan="1">12.7 (2.8)</td><td valign="top" rowspan="1" colspan="1">14.5 (3.6)</td><td valign="top" rowspan="1" colspan="1">13.7 (2.9)</td></tr></tbody></table><table-wrap-foot><fn><p>M:F, male:female; BDI, Beck Depression Inventory; IVE, Eysenck                                Impulsiveness (Imp)-Venturesomeness (Vent)-Empathy (Emp)                                Questionnaire.</p><p><sup>a</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 vs.                                Drug-na&#x000ef;ve controls.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>The information sampling task</title><p>The task was administered on a touch-sensitive 10.5&#x000a0;inch monitor.                    Subjects completed a single practice trial, followed by 10 trials in each of two                    conditions: the Fixed Reward (FR) condition and the Reward Conflict (RC)                    condition. Condition order was counter-balanced across subjects. On each trial,                    subjects were presented with a 5&#x000a0;&#x000d7;&#x000a0;5 matrix of grey                    boxes, with two larger coloured panels at the foot of the screen. Touching a                    grey box caused the box to open (immediately) to reveal one of the two colours                    at the foot of the screen. The subject was asked to decide which colour was in                    the majority of the 25 boxes. They were told &#x02018;It is entirely up to                    you how many boxes you open before making your decision&#x02019; [for                    complete instructions, see <xref ref-type="bibr" rid="R6">Clark, <italic>et                        al.</italic> (2006)</xref>]. To indicate their decision, the subject touched                    the corresponding panel at the foot of the screen, whereupon the remaining boxes                    were uncovered and a feedback message &#x02018;Correct! You have won [x]                    points&#x02019; or &#x02018;Wrong! You have lost 100 points&#x02019;                    was presented immediately, for 2&#x000a0;seconds. In the FR condition, the                    subject was awarded 100 points for a correct response, irrespective of the                    number of boxes opened. In the RC condition, 250 points were available to win at                    the start of the trial, which decreased by 10 points with each box opened,                    thereby creating a conflict between the level of certainty and the reward                    available. Incorrect responses yielded 100 points deduction in either condition.                    In both conditions, the inter-trial interval (ITI) was of variable delay                    (minimum 1s) such that the minimum interval between trial onsets was                    30&#x000a0;s (e.g. if the trial was completed in 20&#x000a0;s, the ITI was                    10&#x000a0;s). This feature was inserted to counteract impulsive behaviour due                    to delay aversion.</p><p>Performance was indexed by the average number of boxes opened, but in addition,                    the probability of making a correct choice at the point of decision was                    calculated on each trial [<italic>P</italic>(Correct); see <xref ref-type="bibr" rid="R6">Clark, <italic>et al</italic>. (2006)</xref> for formula]. Whilst                    these two variables are typically correlated with one another, under some                    circumstances the number of boxes opened can be a limited index of the                    information available; for example, 20 boxes may be distributed 10:10                    [<italic>P</italic>(Correct)&#x000a0;=&#x000a0;0.50] or 15:5                    [<italic>P</italic>(Correct)&#x000a0;=&#x000a0;1.0]. Consequently, the                        <italic>P</italic>(Correct) variable is related more directly to the levels                    of certainty tolerated during decision-making, and was therefore the primary                    variable for analysis. The number of errors was also recorded to test the impact                    of reduced information sampling on decision-making accuracy.</p></sec><sec><title>Statistical analysis</title><p>Data were analysed with SPSS (SPSS Inc, Chicago, Illinois, USA) version 14 using                    two-tailed parametric tests thresholded at                    <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05. Demographic and                    questionnaire data were analysed using one-way ANOVA and chi-squared tests as                    appropriate. The drug and alcohol use data were analysed with one-way ANOVA                    where normality assumptions were met, but in the most part, were not normally                    distributed and were analysed with nonparametric tests (Mann&#x02013;Whitney                    and Kruskal&#x02013;Wallis tests). IST performance was analysed using                    mixed-model ANOVA. Significant ANOVA group differences were decomposed using                    Tukey&#x02019;s <italic>post hoc</italic> tests, or Tamhane&#x02019;s T2                    where variances were unequal.</p></sec></sec><sec><title>Results</title><sec><title>Demographic and drug use characteristics</title><p>The four groups did not differ significantly in NART-estimated verbal IQ                        (<italic>F</italic><sub>3,90</sub>&#x000a0;=&#x000a0;1.49,                    <italic>P</italic>&#x000a0;=&#x000a0;0.224), but the gender ratio differed                    significantly across groups (&#x003c7;<sup>2</sup>&#x000a0;=&#x000a0;8.81,                        <italic>P</italic>&#x000a0;=&#x000a0;0.031) (see <xref ref-type="table" rid="tbl1001">Table&#x000a0;1</xref>). The ANOVA for group differences in                    ageapproached significance                    (<italic>F</italic><sub>3,90</sub>&#x000a0;=&#x000a0;2.36,                    <italic>P</italic>&#x000a0;=&#x000a0;0.077), due to slightly older age in the                    Ex-ecstasy group, although no <italic>post hoc</italic> tests were significant.                    There was a significant group difference in BDI score                        (<italic>F</italic><sub>3,90</sub>&#x000a0;=&#x000a0;5.59,                    <italic>P</italic>&#x000a0;=&#x000a0;0.001), due to elevated self-reported                    depression in the ecstasy and Ex-ecstasy groups in comparison to                    drug-na&#x000ef;ve controls (Tamhane&#x02019;s T2,                    <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 and                    <italic>P</italic>&#x000a0;=&#x000a0;0.038 respectively). Neither BDI score                    nor age was significantly correlated with IST performance                        (<italic>r</italic><sub>94</sub>&#x000a0;=&#x000a0;0.013 and                        <italic>r</italic><sub>94</sub>&#x000a0;=&#x000a0;0.177 respectively), so                    these variables were not considered as covariates. There was a significant group                    difference in self-reported impulsivity on the Eysenck IVE                        (<italic>F</italic><sub>3,90</sub>&#x000a0;=&#x000a0;5.03,                    <italic>P</italic>&#x000a0;=&#x000a0;0.003) due to elevated scores in the                    Current ecstasy and Ex-ecstasy groups in comparison to drug-na&#x000ef;ve                    controls (Tukey&#x02019;s, <italic>P</italic>&#x000a0;=&#x000a0;0.007 and                        <italic>P</italic>&#x000a0;=&#x000a0;0.006 respectively); the cannabis                    group did not differ from drug-na&#x000ef;ve controls                    (<italic>P</italic>&#x000a0;=&#x000a0;0.469). There were no group differences                    on the Venturesomeness                    (<italic>F</italic><sub>3,90</sub>&#x000a0;=&#x000a0;0.866,                    <italic>P</italic>&#x000a0;=&#x000a0;0.462) or Empathy                        (<italic>F</italic><sub>3,90</sub>&#x000a0;=&#x000a0;2.46,                    <italic>P</italic>&#x000a0;=&#x000a0;0.067) subscales.</p><p>Drug and alcohol use data are displayed in <xref ref-type="table" rid="tbl1002">Table&#x000a0;2</xref>. All subjects consumed alcohol, although                    consumption (units/month) differed significantly                    (<italic>F</italic><sub>3,90</sub>&#x000a0;=&#x000a0;5.8,                    <italic>P</italic>&#x000a0;=&#x000a0;0.001) with the Current ecstasy group                    consuming more than that of the drug-na&#x000ef;ve controls and cannabis users                    (Tamhane&#x02019;s T2; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001                    and <italic>P</italic>&#x000a0;=&#x000a0;0.001 respectively). All subjects in                    the three drug groups smoked cigarettes, with no differences in monthly                    consumption (<italic>F</italic><sub>2,72</sub>&#x000a0;=&#x000a0;1.7,                        <italic>P</italic>&#x000a0;=&#x000a0;0.191). The Current ecstasy and                    Ex-ecstasy groups were comparable in terms of lifetime ecstasy exposure                    (Mann&#x02013;Whitney test; <italic>Z</italic>&#x000a0;=&#x000a0;0.52,                        <italic>P</italic>&#x000a0;=&#x000a0;0.606) and highest regular dosage                        (<italic>Z</italic>&#x000a0;=&#x000a0;1.2,                    <italic>P</italic>&#x000a0;=&#x000a0;0.219), but the Current ecstasy group                    reported higher peak single dose intake (i.e. the maximum number of tablets                    consumed on a single occasion) (<italic>Z</italic>&#x000a0;=&#x000a0;2.6,                        <italic>P</italic>&#x000a0;=&#x000a0;0.009), whereas the Ex-ecstasy group                    reported greater maximum frequency of usage per month                    (<italic>Z</italic>&#x000a0;=&#x000a0;2.3,                    <italic>P</italic>&#x000a0;=&#x000a0;0.019). As expected, the Ex-ecstasy group                    also had a longer abstinence period (<italic>Z</italic>&#x000a0;=&#x000a0;5.6,                        <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001). The cannabis users                    reported similar current cannabis usage (joints per month) to the two ecstasy                    groups (Kruskal&#x02013;Wallis                    &#x003c7;<sup>2</sup>&#x000a0;=&#x000a0;4.5,                    <italic>P</italic>&#x000a0;=&#x000a0;0.106), although the two ecstasy groups                    reported more total lifetime usage of cannabis                    (&#x003c7;<sup>2</sup>&#x000a0;=&#x000a0;6.1,                    <italic>P</italic>&#x000a0;=&#x000a0;0.047). Subjects in the two ecstasy                    groups were more likely than the cannabis group to have ever used psilocybin                    (Fisher&#x02019;s Exact &#x003c7;<sup>2</sup>&#x000a0;=&#x000a0;19.1,                        <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001), LSD                        (&#x003c7;<sup>2</sup>&#x000a0;=&#x000a0;16.2,                    <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001), amphetamine                        (&#x003c7;<sup>2</sup>&#x000a0;=&#x000a0;21.2,                    <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001), amyl nitrate                        (&#x003c7;<sup>2</sup>&#x000a0;=&#x000a0;21.8,                    <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001), ketamine                        (&#x003c7;<sup>2</sup>&#x000a0;=&#x000a0;18.6,                    <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001), cocaine                        (&#x003c7;<sup>2</sup>&#x000a0;=&#x000a0;17.9,                    <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) and opiates                        (&#x003c7;<sup>2</sup>&#x000a0;=&#x000a0;12.4,                    <italic>P</italic>&#x000a0;=&#x000a0;0.001); although, there was modest usage                    of most of these substances in the cannabis group.</p><table-wrap id="tbl1002" position="float"><label>Table&#x000a0;2</label><caption><p>Self-reported drug and alcohol use in the four groups [mean (SD)]</p></caption><table frame="hsides" rules="groups"><colgroup span="5"><col width="70" span="1"/><col width="21" align="char" char="(" span="1"/><col width="31.5" span="1"/><col width="31.5" span="1"/><col width="21" span="1"/></colgroup><thead><tr><td valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Drug-na&#x000ef;ve</td><td align="left" valign="top" rowspan="1" colspan="1">Ecstasy</td><td align="left" valign="top" rowspan="1" colspan="1">Ex-ecstasy</td><td align="left" valign="top" rowspan="1" colspan="1">Cannabis</td></tr><tr><td colspan="5" rowspan="1"/></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Alcohol (<italic>N</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="left" valign="top" rowspan="1" colspan="1">46</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">15</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Units last month</td><td valign="top" rowspan="1" colspan="1">32.5 (28.1)</td><td valign="top" rowspan="1" colspan="1">101.8 (99.5)</td><td valign="top" rowspan="1" colspan="1">43 (66.8)</td><td valign="top" rowspan="1" colspan="1">34.6 (25.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tobacco (<italic>N</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">46</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">15</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Cigarettes last month</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td valign="top" rowspan="1" colspan="1">172.4 (191.5)</td><td valign="top" rowspan="1" colspan="1">238.8 (239.3)</td><td valign="top" rowspan="1" colspan="1">107.0 (140.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cannabis (<italic>N</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1">46</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">15</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Life joints</td><td valign="top" rowspan="1" colspan="1">7.1 (4.5)</td><td valign="top" rowspan="1" colspan="1">6707.7 (9244.1)</td><td valign="top" rowspan="1" colspan="1">10&#x000a0;379.2 (18&#x000a0;546.5)</td><td valign="top" rowspan="1" colspan="1">2704.2 (6221.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Joints last month</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td valign="top" rowspan="1" colspan="1">53.1 (80.9)</td><td valign="top" rowspan="1" colspan="1">52.1 (121.9)</td><td valign="top" rowspan="1" colspan="1">31.3 (53.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ecstasy (<italic>N</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">46</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Life tablets</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td valign="top" rowspan="1" colspan="1">609.1 (703.2)</td><td valign="top" rowspan="1" colspan="1">1000.8 (1792.4)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Peak intake (single dose)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td valign="top" rowspan="1" colspan="1">8.9 (4.5)</td><td valign="top" rowspan="1" colspan="1">5.3 (2.8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Highest regular dose                                    (tablets)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td valign="top" rowspan="1" colspan="1">4.7 (2.5)</td><td valign="top" rowspan="1" colspan="1">4.0 (2.8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Highest regular frequency                                    (times/month)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td valign="top" rowspan="1" colspan="1">5.7 (3.8)</td><td valign="top" rowspan="1" colspan="1">11.2 (8.0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Time since last taken                                    (days)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td valign="top" rowspan="1" colspan="1">71.9 (66.0)</td><td valign="top" rowspan="1" colspan="1">1059.4 (1105.8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Psilocybin (<italic>N</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">38</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Times in lifetime</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td valign="top" rowspan="1" colspan="1">14.1 (20.5)</td><td valign="top" rowspan="1" colspan="1">14.3 (23.4)</td><td valign="top" rowspan="1" colspan="1">3.5 (2.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LSD (<italic>N</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">31</td><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="left" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Trips in lifetime</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td valign="top" rowspan="1" colspan="1">69.7 (165.2)</td><td valign="top" rowspan="1" colspan="1">52.6 (115.3)</td><td valign="top" rowspan="1" colspan="1">3.0 (1.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Amphetamine (<italic>N</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">40</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Grams in lifetime</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td valign="top" rowspan="1" colspan="1">401.8 (1361.3)</td><td valign="top" rowspan="1" colspan="1">268.6 (371.8)</td><td valign="top" rowspan="1" colspan="1">78.8 (155.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Amyl nitrate (<italic>N</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">37</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Times in lifetime</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td valign="top" rowspan="1" colspan="1">67.7 (255.8)</td><td valign="top" rowspan="1" colspan="1">8.4 (6.8)</td><td valign="top" rowspan="1" colspan="1">29.0 (26.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ketamine (<italic>N</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">27</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Grams in lifetime</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td valign="top" rowspan="1" colspan="1">11.6 (18.8)</td><td valign="top" rowspan="1" colspan="1">6.2 (6.9)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cocaine (<italic>N</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">41</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Grams in lifetime</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td valign="top" rowspan="1" colspan="1">87.6 (165.8)</td><td valign="top" rowspan="1" colspan="1">214 (687.5)</td><td valign="top" rowspan="1" colspan="1">7.9 (9.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Opiates (<italic>N</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Grams in lifetime</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td valign="top" rowspan="1" colspan="1">9.2 (24.2)</td><td valign="top" rowspan="1" colspan="1">76.8 (85.0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table></table-wrap></sec><sec><title>IST performance</title><p>A mixed-model ANOVA of <italic>P</italic>(Correct) data (the probability of being                    correct at the point of decision), with Condition (Fixed Reward, Reward                    Conflict) as a within-subjects variable and Group and Gender as between-subjects                    variables, revealed a significant main effect of Condition                        (<italic>F</italic><sub>1,86</sub>&#x000a0;=&#x000a0;95.8,                    <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001). As expected, subjects                    tolerated more uncertainty [a lower <italic>P</italic>(Correct)] in the Reward                    Conflict condition than the Fixed Reward condition, thus demonstrating                    sensitivity to the task contingencies (see <xref ref-type="table" rid="tbl1003">Table&#x000a0;3</xref>). There was a significant main effect of Group                        (<italic>F</italic><sub>3,86</sub>&#x000a0;=&#x000a0;5.45,                    <italic>P</italic>&#x000a0;=&#x000a0;0.002), and a significant                    Group&#x000a0;&#x000d7;&#x000a0;Gender interaction                        (<italic>F</italic><sub>3,86</sub>&#x000a0;=&#x000a0;4.53,                    <italic>P</italic>&#x000a0;=&#x000a0;0.005). The other terms did not attain                    significance (all <italic>F</italic>&#x000a0;&#x0003c;&#x000a0;1), and                    notably, the Group&#x000a0;&#x000d7;&#x000a0;Condition interaction was not                    significant (<italic>F</italic><sub>3,86</sub>&#x000a0;=&#x000a0;0.621,                        <italic>P</italic>&#x000a0;=&#x000a0;0.603) suggesting comparable                    sensitivity to the change in conditions across groups. <italic>Post hoc</italic>                    group comparisons (Tukey&#x02019;s) collapsed across Condition showed that                    the cannabis users opened significantly fewer boxes compared with the Ex-ecstasy                    group (<italic>P</italic>&#x000a0;=&#x000a0;0.013), and differed at trend from                    the Current ecstasy users (<italic>P</italic>&#x000a0;=&#x000a0;0.076) and the                    drug-na&#x000ef;ve controls (<italic>P</italic>&#x000a0;=&#x000a0;0.078).                    There were no differences between the ecstasy groups and drug-na&#x000ef;ve                    controls (see <xref ref-type="fig" rid="F1">Figure&#x000a0;1</xref>). An                        <italic>a priori</italic> planned contrast confirmed a significant                    difference between the cannabis users and the drug-naive controls                        (<italic>t</italic><sub>32</sub>&#x000a0;=&#x000a0;2.31,                    <italic>P</italic>&#x000a0;=&#x000a0;0.027) with a large effect size                    (Cohen&#x02019;s                    <italic>d</italic>&#x000a0;<italic>=</italic>&#x000a0;0.81).</p><table-wrap id="tbl1003" position="float"><label>Table&#x000a0;3</label><caption><p>Performance on the Information Sampling Task in the four groups [mean                            (SD)]</p></caption><table frame="hsides" rules="groups"><colgroup span="5"><col width="35" span="1"/><col width="35" align="char" char="(" span="1"/><col width="35" align="char" char="(" span="1"/><col width="35" align="char" char="(" span="1"/><col width="35" align="char" char="(" span="1"/></colgroup><thead><tr><td valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Drug-naive</td><td align="left" valign="top" rowspan="1" colspan="1">Ecstasy</td><td align="left" valign="top" rowspan="1" colspan="1">Ex-ecstasy</td><td align="left" valign="top" rowspan="1" colspan="1">Cannabis</td></tr><tr><td colspan="5" rowspan="1"/></tr></thead><tbody><tr><td colspan="5" align="left" valign="top" rowspan="1">Fixed reward</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;<italic>P</italic>(Correct)</td><td valign="top" rowspan="1" colspan="1">0.85 (0.10)</td><td valign="top" rowspan="1" colspan="1">0.84 (0.09)</td><td valign="top" rowspan="1" colspan="1">0.86 (0.08)</td><td valign="top" rowspan="1" colspan="1">0.78 (0.07)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Boxes</td><td valign="top" rowspan="1" colspan="1">14.8 (4.6)</td><td valign="top" rowspan="1" colspan="1">15.4 (4.4)</td><td valign="top" rowspan="1" colspan="1">15.7 (4.1)</td><td valign="top" rowspan="1" colspan="1">11.8 (3.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Errors</td><td valign="top" rowspan="1" colspan="1">1.0 (1.1)</td><td valign="top" rowspan="1" colspan="1">1.3 (1.1)</td><td valign="top" rowspan="1" colspan="1">1.1 (1.0)</td><td valign="top" rowspan="1" colspan="1">1.8 (1.2)</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Reward conflict</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;<italic>P</italic>(Correct)</td><td valign="top" rowspan="1" colspan="1">0.74 (0.06)</td><td valign="top" rowspan="1" colspan="1">0.73 (0.06)</td><td valign="top" rowspan="1" colspan="1">0.77 (0.07)</td><td valign="top" rowspan="1" colspan="1">0.70 (0.07)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Boxes</td><td valign="top" rowspan="1" colspan="1">8.9 (2.5)</td><td valign="top" rowspan="1" colspan="1">9.3 (3.4)</td><td valign="top" rowspan="1" colspan="1">11.2 (3.6)</td><td valign="top" rowspan="1" colspan="1">8.2 (3.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Errors</td><td valign="top" rowspan="1" colspan="1">2.5 (1.2)</td><td valign="top" rowspan="1" colspan="1">2.3 (1.3)</td><td valign="top" rowspan="1" colspan="1">2.2 (1.4)</td><td valign="top" rowspan="1" colspan="1">2.1 (1.2)</td></tr></tbody></table></table-wrap><fig id="F1" position="float"><label>Figure&#x000a0;1</label><caption><p>Performance on the Information Sampling Test in the Current and                            Ex-ecstasy users, cannabis users and drug-na&#x000ef;ve controls, in                            terms of the probability of making a correct response at the time of                            decision [<italic>P</italic>(Correct)]. These data are collapsed across                            the two conditions of the task (Fixed Reward and Reward Conflict) given                            the absence of a significant group &#x000d7; condition interaction                            term. Error bars display standard error of the mean. The asterisk                            signifies <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 in the                            comparison against drug-na&#x000ef;ve controls.</p></caption><graphic xlink:href="jop089587f1"/></fig><p>A simple main effects analysis of the Group&#x000a0;&#x000d7;&#x000a0;Gender                    interaction assessed the effect of Group in males and females separately,                    collapsed across condition. The one-way ANOVA was significant for male subjects                        (<italic>F</italic><sub>3,52</sub>&#x000a0;=&#x000a0;6.77,                    <italic>P</italic>&#x000a0;=&#x000a0;0.001), where <italic>post hoc</italic>                    comparisons demonstrated significantly reduced information sampling in male                    cannabis users compared to each of the other three groups (Tukey&#x02019;s:                    Ex-ecstasy users <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001; Current                    ecstasy users <italic>P</italic>&#x000a0;=&#x000a0;0.035; drug-na&#x000ef;ve                    controls <italic>P</italic>&#x000a0;=&#x000a0;0.038). The one-way ANOVA in                    female subjects was not significant                    (<italic>F</italic><sub>3,34</sub>&#x000a0;=&#x000a0;1.46,                    <italic>P</italic>&#x000a0;=&#x000a0;0.242), but numerically, the female                    cannabis group displayed the lowest information sampling of the four groups. A                        <italic>post hoc</italic> analysis compared the extent of cannabis usage                    (the main drug of abuse) across male and female subjects in the polydrug group,                    and found similar lifetime joints                    (<italic>t</italic><sub>4.1</sub>&#x000a0;=&#x000a0;1.05,                    <italic>P</italic>&#x000a0;=&#x000a0;0.350) and joints in the last month                        (<italic>t</italic><sub>4.5</sub>&#x000a0;=&#x000a0;1.1,                    <italic>P</italic>&#x000a0;=&#x000a0;0.324) in the male and female                    participants, suggesting that the influence of gender on the IST performance was                    not simply due to differences in drug usage.</p><p>Analysis of the number of boxes opened on the IST revealed a qualitatively                    similar pattern of group differences to <italic>P</italic>(Correct) data, which                    is unsurprising given <italic>r</italic>&#x000a0;&#x0003e;&#x000a0;0.9 correlations                    between these variables (see task description in Methods). There was a                    significant main effect of group in the mixed model ANOVA                        (<italic>F</italic><sub>3,90</sub>&#x000a0;=&#x000a0;5.83,                    <italic>P</italic>&#x000a0;=&#x000a0;0.001) due to reduced information                    sampling in the cannabis users compared with the Ex-ecstasy group                    (Tukey&#x02019;s <italic>P</italic>&#x000a0;=&#x000a0;0.020) and the                    Current ecstasy group (<italic>P</italic>&#x000a0;=&#x000a0;0.059). There were                    greater group differences in the male subjects                    (<italic>F</italic><sub>3,52</sub>&#x000a0;=&#x000a0;7.07,                    <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) than in the females                        (<italic>F</italic><sub>3,34</sub>&#x000a0;=&#x000a0;1.83,                    <italic>P</italic>&#x000a0;=&#x000a0;0.161). Errors committed on the IST was                    inversely correlated with boxes opened                    (<italic>r</italic><sub>94</sub>&#x000a0;=&#x000a0;&#x02013;0.526,                        <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) and                    <italic>P</italic>(Correct)                    (<italic>r</italic><sub>94</sub>&#x000a0;=&#x000a0;&#x02013;0.566,                        <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001), confirming a core                    principle of reflection impulsivity. However, the mixed-model ANOVA of                    IST-errors found no significant main effect of Group                        (<italic>F</italic><sub>3,90</sub>&#x000a0;=&#x000a0;0.258,                    <italic>P</italic>&#x000a0;=&#x000a0;0.855) or                    Group&#x000a0;&#x000d7;&#x000a0;Condition interaction                        (<italic>F</italic><sub>3,90</sub>&#x000a0;=&#x000a0;1.80,                    <italic>P</italic>&#x000a0;=&#x000a0;0.152). Finally, we examined the                    correlation between Impulsivity and Venturesomeness scales of the Eysenck IVE,                    and IST performance [<italic>P</italic>(Correct) collapsed across condition].                    There was no significant association in the overall group (Impulsivity:                        <italic>r</italic><sub>94</sub>&#x000a0;=&#x000a0;0.003,                    <italic>P</italic>&#x000a0;=&#x000a0;0.974; Venturesomeness                        <italic>r</italic><sub>94</sub>&#x000a0;=&#x000a0;0.043,                    <italic>P</italic>&#x000a0;=&#x000a0;0.678) or in any of the four groups                        (<italic>r</italic>&#x000a0;=&#x000a0;&#x02212;0.33 to +0.19).</p></sec></sec><sec><title>Discussion</title><p>The present study used a recently developed IST to measure reflection impulsivity in                current and former ecstasy users, cannabis users and drug-na&#x000ef;ve controls.                In the Fixed Reward condition (where there was no penalty for sampling further                information), the drug-na&#x000ef;ve control group sampled information to a point                of 85% certainty (95% confidence intervals: 80&#x02013;89%), similar to healthy                performance in our previous study (<xref ref-type="bibr" rid="R6">Clark, <italic>et                        al</italic>., 2006</xref>). Moreover, the number of boxes opened and the                level of certainty tolerated during decision-making were both inversely correlated                with incorrect judgments in the overall sample                (<italic>n</italic>&#x000a0;=&#x000a0;94). This demonstrates the central feature                of a test of reflection impulsivity: the extent of information sampling is                predictive of eventual decision accuracy (<xref ref-type="bibr" rid="R14">Evenden,                    1999a</xref>).</p><p>Regular cannabis users sampled significantly fewer boxes on the IST and tolerated                more uncertainty in making the correct decision, compared with the other groups.                This difference was statistically significant in a planned comparison against the                drug-na&#x000ef;ve control group, and the cannabis users sampled significantly less                information than the Ex-ecstasy group in the more conservative Tukey&#x02019;s                    <italic>post hoc</italic> group comparisons. The cannabis users altered their                information sampling behaviour to a similar degree between the Fixed Reward and                Reward Decrement conditions, compared with the other groups (i.e. the nonsignificant                Group&#x000a0;&#x000d7;&#x000a0;Condition interaction term). This indicates                comparable sensitivity to the change in reward contingencies, and suggests that the                reduced information sampling behaviour was not simply attributable to a lack of                motivation in the cannabis group. These data are also consistent with a report of                risky decision-making (on the Iowa Gambling Task) in regular marijuana users (<xref ref-type="bibr" rid="R54">Whitlow, <italic>et al</italic>., 2004</xref>).                Decision-making impairments on complex tests like the Iowa Gambling Task may                putatively arise from a failure of pre-decisional information sampling or                evaluation. Our findings extend our earlier observation of reduced information                sampling in current and former users of amphetamines or opiates, who met DSM-IV                criteria for dependence (<xref ref-type="bibr" rid="R6">Clark, <italic>et                    al</italic>., 2006</xref>). Given the presence of this effect across multiple                substances of abuse with distinct pharmacological targets (amphetamines, opiates,                cannabis), we suggest that impaired reflection impulsivity may represent a cognitive                style associated with the pre-existing vulnerability to recreational drug use and                later dependence, consistent with data from high-risk prospective studies (<xref ref-type="bibr" rid="R41">Nigg, <italic>et al</italic>., 2006</xref>; <xref ref-type="bibr" rid="R49">Tarter, <italic>et al.</italic>, 2004</xref>).</p><p>We were unable to detect any significant group differences on the IST between the                ecstasy-using groups and the drug-na&#x000ef;ve controls. Several other studies                have failed to substantiate the link between ecstasy use and other aspects of                impulsivity, including the Stroop and Go/No Go tests (<xref ref-type="bibr" rid="R9">Dafters, 2006</xref>; <xref ref-type="bibr" rid="R20">Fox, <italic>et                    al</italic>., 2002</xref>; <xref ref-type="bibr" rid="R24">Gouzoulis-Mayfrank,                        <italic>et al</italic>., 2003</xref>). However, our findings fail to                replicate several studies that have demonstrated impulsivity in regular ecstasy                users on another widely used test of reflection, the MFFT (<xref ref-type="bibr" rid="R37">Morgan, 1998</xref>; <xref ref-type="bibr" rid="R39">Morgan,                        <italic>et al.</italic>, 2002</xref>; <xref ref-type="bibr" rid="R38">Morgan, <italic>et al</italic>., 2006</xref>; <xref ref-type="bibr" rid="R44">Quednow, <italic>et al</italic>., 2007</xref>). The ecstasy users in the                present study reported moderate use of other illicit substances, including similar                cannabis usage to the cannabis group. The two ecstasy groups were also more likely                than the cannabis group to have used a range of other substances, including                amphetamine, cocaine and opiates. Consequently, if reduced reflection is a                pre-existing cognitive style associated with general recreational drug use, we would                expect this effect to have also been present in the two ecstasy groups. Lack of                statistical power seems unlikely to explain the negative result, as the ecstasy                groups actually sampled more information (in terms of boxes opened), on average,                than the drug-na&#x000ef;ve controls. In addition, the group size of 46 current                ecstasy users is reasonably large for studies of this kind, and the level of ecstasy                consumption was considerable (e.g. lifetime usage means of 609 and 1001 in the                Current and Ex-ecstasy groups respectively), compared with the wider                neuropsychological literature [e.g. 458 tablets in <xref ref-type="bibr" rid="R44">Quednow, <italic>et al.</italic> (2007)</xref>].</p><p>There are several possible explanations for the discrepancy with the studies by                Morgan, <italic>et al.</italic> (1998, 2002, 2006), and <xref ref-type="bibr" rid="R44">Quednow, <italic>et al</italic>. (2007)</xref>. One consideration is                the duration of abstinence from ecstasy, which was relatively long in the present                study (&#x0003e;&#x000a0;3&#x000a0;weeks) but much shorter in the positive studies,                ranging from 3&#x000a0;days (mean 17&#x000a0;days; Quednow, <italic>et                al</italic>., 2007) to 5&#x000a0;days (Morgan, <italic>et al</italic>., 2005).                Studies in experimental animals reveal recoverable reductions in serotonin function                1&#x02013;2&#x000a0;weeks after dosing that do not indicate neurotoxicity (<xref ref-type="bibr" rid="R23">Gouzoulis-Mayfrank &#x00026; Daumann 2006</xref>). In                addition, studies of other drugs indicate that short-term withdrawal may exacerbate                behavioural impulsivity (see below). <xref ref-type="bibr" rid="R33">Lyvers and                    Hasking (2004)</xref> recommended a 1-month abstinence window for                neuropsychological studies. Hence, the positive MFFT results by Morgan, <italic>et                    al.</italic> and Quednow, <italic>et al.</italic> could be caused by semi-acute                effects of serotonin depletion upon task performance.</p><p>We have shown previously that IST performance is related to MFFT performance in                healthy volunteers: fast, inaccurate responders on the MFFT opened significantly                fewer boxes on the IST than slow, accurate responders (<xref ref-type="bibr" rid="R7">Clark, <italic>et al.</italic>, 2003</xref>). However, the MFFT                involves a number of extraneous additional processes, including visual search,                visual working memory and strategy implementation, which may be independently                impaired in regular ecstasy users (<xref ref-type="bibr" rid="R20">Fox, <italic>et                        al</italic>., 2002</xref>; <xref ref-type="bibr" rid="R25">Halpern,                        <italic>et al</italic>., 2004</xref>; <xref ref-type="bibr" rid="R53">Wareing, <italic>et al</italic>., 2005</xref>). The design of the IST                explicitly aimed to minimize these extraneous demands. In the MFFT study by <xref ref-type="bibr" rid="R37">Morgan (1998)</xref>, there was a group difference in                MFFT accuracy but not latency, which may be plausibly explained as a more general                impairment. Other studies, however, reported significant differences in both speed                and accuracy (<xref ref-type="bibr" rid="R38">Morgan, <italic>et al</italic>.,                2006</xref>; <xref ref-type="bibr" rid="R39">Morgan, <italic>et al</italic>.,                2002</xref>), which is likely to indicate impulsivity.</p><p>Additional factors may mediate the deficits in laboratory impulsivity in ecstasy                users, and contribute to variability across studies. Gender may be one such                variable: in the present study, the reduced information sampling in the cannabis                group was mainly attributable to the male subjects, and other studies also described                greater neuropsychological impairments in male drug users than in female drug users                    (<xref ref-type="bibr" rid="R13">Ersche, <italic>et al</italic>., 2006</xref>;                    <xref ref-type="bibr" rid="R48">Stout, <italic>et al</italic>., 2005</xref>),                including ecstasy users (<xref ref-type="bibr" rid="R52">von Geusau, <italic>et                    al</italic>., 2004</xref>). In addition to gender, studies of other groups of                drug-users with the delay discounting paradigm have indicated greater impulsivity in                current users compared with ex-users (<xref ref-type="bibr" rid="R2">Bickel,                        <italic>et al</italic>., 1999</xref>; <xref ref-type="bibr" rid="R43">Petry,                    2001</xref>). Two distinct mechanisms may contribute to this effect: withdrawal                and/or craving may exacerbate impulsivity in current users (<xref ref-type="bibr" rid="R17">Field, <italic>et al</italic>., 2006</xref>; <xref ref-type="bibr" rid="R21">Giordano, <italic>et al</italic>., 2002</xref>), but also, less                impulsive drug users may be more capable of achieving successful abstinence (<xref ref-type="bibr" rid="R2">Bickel, <italic>et al</italic>., 1999</xref>). In the                present data, there was no evidence of the latter effect, as the Current and                Ex-ecstasy users scored similarly on the IVE and IST measures. It is possible that                the periods of abstinence from ecstasy in the Current (&#x0003e;3&#x000a0;weeks) and Ex                (&#x0003e;1&#x000a0;year) ecstasy groups had attenuated impulsivity compared with the                cannabis group, although against this explanation, the ecstasy groups did report                moderate recent usage of other substances, including similar cannabis usage to the                cannabis group in the past month.</p><p>Whilst we found no evidence of laboratory impulsivity on the IST in the ecstasy                group, self-reported impulsivity on the Eysenck IVE questionnaire was significantly                elevated in the current and former ecstasy users. Questionnaire impulsivity should                indicate trait dispositions that are present prior to the initiation of drug use;                for example, <xref ref-type="bibr" rid="R11">de Win, <italic>et al</italic>.                (2006)</xref> showed no change on the Barratt Impulsiveness Scale before and after                initiation of ecstasy use in a prospective cohort. Previous studies suggest large                variability in trait impulsivity in ecstasy users, with a number of studies                reporting elevations (<xref ref-type="bibr" rid="R5">Butler and Montgomery,                2004</xref>; <xref ref-type="bibr" rid="R37">Morgan, 1998</xref>; <xref ref-type="bibr" rid="R42">Parrott, <italic>et al</italic>., 2000</xref>), but                other studies finding no differences (<xref ref-type="bibr" rid="R50">Travers and                    Lyvers, 2005</xref>) and one study even finding a significant reduction (<xref ref-type="bibr" rid="R34">McCann, <italic>et al</italic>., 1994</xref>). In our                data, there was no association between the IVE score and performance on the IST.                These data highlight the multi-factorial nature of impulsivity, and are in keeping                with a number of other reports showing limited associations between state                (laboratory) and trait (questionnaire) measures of impulsivity (<xref ref-type="bibr" rid="R12">Dom, <italic>et al</italic>., 2007</xref>; <xref ref-type="bibr" rid="R29">Lijffijt, <italic>et al</italic>., 2004</xref>; <xref ref-type="bibr" rid="R45">Reynolds, <italic>et al</italic>., 2006</xref>).                Questionnaire ratings indicate general behavioural tendencies across a variety of                situations, and rely on a subjective perception of one&#x02019;s behaviour. In                contrast, laboratory tasks provide an objective measure of a specific facet of                impulsivity at a single point in time. Weak correlations between these two sets of                variables may be a realistic expectation. Similarly, our findings do not refute the                possibility that other domains of laboratory impulsivity (e.g. delay discounting,                response inhibition) may be impaired in ecstasy groups. As discussed above, there                are inconsistent findings using tasks of response inhibition in ecstasy users (<xref ref-type="bibr" rid="R9">Dafters, 2006</xref>; <xref ref-type="bibr" rid="R20">Fox, <italic>et al</italic>., 2002</xref>; <xref ref-type="bibr" rid="R24">Gouzoulis-Mayfrank, <italic>et al</italic>., 2003</xref>), and to our                knowledge, no studies have yet explored delay-discounting in regular ecstasy users.</p><p>Some further limitations of the present study should be noted. Whilst the number of                current ecstasy users was large, the group sizes for the former ecstasy users and                the cannabis users were considerably smaller. In particular, the analyses split by                gender should be treated as preliminary due to the reduced power, and need to be                confirmed in a larger sample. In addition, the two groups of ecstasy users showed a                high degree of polydrug use, although this arguably renders their intact IST                performance even more surprising.</p><p>In conclusion, these data support the position of reflection impulsivity as a                relevant cognitive dimension in regular drug users, by demonstrating reduced                information sampling in a group of regular cannabis users. Reduced reflection is                likely to have a detrimental impact on wider-scale decision-making capabilities,                with potential relevance for treatment engagement and the ability to maintain                long-term abstinence. Unexpectedly, the present study found no differences in                reflection in current or former ecstasy users, despite evidence of trait impulsivity                in these subjects. These data appear to challenge a simplistic pathway from ecstasy                consumption to elevated impulsivity via serotonin neurotoxicity.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was funded by a Wellcome Trust programme grant to TWR, BJ Everitt, AC                Roberts and BJS, and a consortium award from the Medical Research Council (UK) and                Wellcome Trust to the Behavioural and Clinical Neurosciences Institute (BCNI). LC is                supported by an Economic and Social Research Council project grant (RES-164-0010).                JPR was supported by a Medical Research Council studentship. This study was                conducted at the Wellcome Trust Clinical Research Facility at                Addenbrooke&#x02019;s Hospital, Cambridge, and we are grateful to the nurses and                administrative staff for their support. The Information Sampling Task is subject to                international patent PCT/GB2004/003136 and is licensed to Cambridge Cognition plc.                LC, JPR, TWR and BJS consult for Cambridge Cognition plc.</p></ack><ref-list><title>References</title><ref id="R1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bickel</surname><given-names>WK</given-names></name><name><surname>Marsch</surname><given-names>LA</given-names></name></person-group> (<year>2001</year>) <article-title>Toward a behavioral economic                        understanding of drug dependence: delay discounting processes.</article-title><source>Addiction</source><volume>96</volume>: <fpage>73</fpage>&#x02013;<lpage>86</lpage><pub-id pub-id-type="pmid">11177521</pub-id></citation></ref><ref id="R2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bickel</surname><given-names>WK</given-names></name><name><surname>Odum</surname><given-names>AL</given-names></name><name><surname>Madden</surname><given-names>GJ</given-names></name></person-group> (<year>1999</year>) <article-title>Impulsivity and cigarette                        smoking: delay discounting in current, never, and ex-smokers.</article-title><source>Psychopharmacology (Berl)</source><volume>146</volume>:                <fpage>447</fpage>&#x02013;<lpage>454</lpage><pub-id pub-id-type="pmid">10550495</pub-id></citation></ref><ref id="R3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bjork</surname><given-names>JM</given-names></name><name><surname>Hommer</surname><given-names>DW</given-names></name><name><surname>Grant</surname><given-names>SJ</given-names></name><name><surname>Danube</surname><given-names>C</given-names></name></person-group> (<year>2004</year>) <article-title>Impulsivity in abstinent                        alcohol-dependent patients: relation to control subjects and type 1-/type                        2-like traits.</article-title><source>Alcohol</source><volume>34</volume>:                <fpage>133</fpage>&#x02013;<lpage>150</lpage><pub-id pub-id-type="pmid">15902907</pub-id></citation></ref><ref id="R4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>J</given-names></name><name><surname>Block</surname><given-names>JH</given-names></name><name><surname>Harrington</surname><given-names>DM</given-names></name></person-group> (<year>1974</year>) <article-title>Some misgivings about the                        matching familiar figures test as a measure of reflection impulsivity.</article-title><source>Dev Psychol</source><volume>10</volume>:                <fpage>611</fpage>&#x02013;<lpage>632</lpage></citation></ref><ref id="R5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>GK</given-names></name><name><surname>Montgomery</surname><given-names>AM</given-names></name></person-group> (<year>2004</year>) <article-title>Impulsivity, risk taking and                        recreational 'ecstasy' (MDMA) use.</article-title><source>Drug Alcohol Depend</source><volume>76</volume>: <fpage>55</fpage>&#x02013;<lpage>62</lpage><pub-id pub-id-type="pmid">15380289</pub-id></citation></ref><ref id="R6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>L</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Ersche</surname><given-names>KD</given-names></name><name><surname>Sahakian</surname><given-names>BJ</given-names></name></person-group> (<year>2006</year>) <article-title>Reflection impulsivity in                        current and former substance users.</article-title><source>Biol Psychiatry</source><volume>60</volume>:                <fpage>515</fpage>&#x02013;<lpage>522</lpage><pub-id pub-id-type="pmid">16448627</pub-id></citation></ref><ref id="R7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>L</given-names></name><name><surname>Roiser</surname><given-names>J</given-names></name><name><surname>Imeson</surname><given-names>L</given-names></name><name><surname>Islam</surname><given-names>S</given-names></name><name><surname>Sonuga-Barke</surname><given-names>EJ</given-names></name><name><surname>Sahakian</surname><given-names>BJ</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name></person-group> (<year>2003</year>) <article-title>Validation of a novel measure                        of reflection impulsivity for use in adult patient populations.</article-title><source>J Psychopharmacol</source><volume>17</volume>(<issue>Suppl.</issue>):                <fpage>A36</fpage></citation></ref><ref id="R8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>L</given-names></name><name><surname>Roiser</surname><given-names>JP</given-names></name><name><surname>Cools</surname><given-names>R</given-names></name><name><surname>Rubinsztein</surname><given-names>DC</given-names></name><name><surname>Sahakian</surname><given-names>BJ</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name></person-group> (<year>2005</year>) <article-title>Stop signal response                        inhibition is not modulated by tryptophan depletion or the serotonin                        transporter polymorphism in healthy volunteers: implications for the 5-HT                        theory of impulsivity.</article-title><source>Psychopharmacology (Berl)</source><volume>182</volume>:                <fpage>570</fpage>&#x02013;<lpage>578</lpage><pub-id pub-id-type="pmid">16163530</pub-id></citation></ref><ref id="R9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dafters</surname><given-names>RI</given-names></name></person-group> (<year>2006</year>) <article-title>Chronic ecstasy (MDMA) use is                        associated with deficits in task-switching but not inhibition or memory                        updating executive functions.</article-title><source>Drug Alcohol Depend</source><volume>83</volume>:                <fpage>181</fpage>&#x02013;<lpage>184</lpage><pub-id pub-id-type="pmid">16316723</pub-id></citation></ref><ref id="R10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dalley</surname><given-names>JW</given-names></name><name><surname>Theobald</surname><given-names>DE</given-names></name><name><surname>Eagle</surname><given-names>DM</given-names></name><name><surname>Passetti</surname><given-names>F</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name></person-group> (<year>2002</year>) <article-title>Deficits in impulse control                        associated with tonically-elevated serotonergic function in rat prefrontal                        cortex.</article-title><source>Neuropsychopharmacology</source><volume>26</volume>:                <fpage>716</fpage>&#x02013;<lpage>728</lpage><pub-id pub-id-type="pmid">12007742</pub-id></citation></ref><ref id="R11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Win</surname><given-names>MM</given-names></name><name><surname>Schilt</surname><given-names>T</given-names></name><name><surname>Reneman</surname><given-names>L</given-names></name><name><surname>Vervaeke</surname><given-names>H</given-names></name><name><surname>Jager</surname><given-names>G</given-names></name><name><surname>Dijkink</surname><given-names>S</given-names></name><name><surname>Booij</surname><given-names>J</given-names></name><name><surname>van den Brink</surname><given-names>W</given-names></name></person-group> (<year>2006</year>) <article-title>Ecstasy use and self-reported                        depression, impulsivity, and sensation seeking: a prospective cohort study.</article-title><source>J Psychopharmacol</source><volume>20</volume>:                <fpage>226</fpage>&#x02013;<lpage>235</lpage><pub-id pub-id-type="pmid">16510480</pub-id></citation></ref><ref id="R12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dom</surname><given-names>G</given-names></name><name><surname>De Wilde</surname><given-names>B</given-names></name><name><surname>Hulstijn</surname><given-names>W</given-names></name><name><surname>Sabbe</surname><given-names>B</given-names></name></person-group> (<year>2007</year>) <article-title>Dimensions of impulsive                        behavior in abstinent alcoholics.</article-title><source>Pers Individ Dif</source><volume>42</volume>:                <fpage>465</fpage>&#x02013;<lpage>476</lpage></citation></ref><ref id="R13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ersche</surname><given-names>KD</given-names></name><name><surname>Clark</surname><given-names>L</given-names></name><name><surname>London</surname><given-names>M</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Sahakian</surname><given-names>BJ</given-names></name></person-group> (<year>2006</year>) <article-title>Profile of executive and                        memory function associated with amphetamine and opiate dependence.</article-title><source>Neuropsychopharmacology</source><volume>31</volume>:                <fpage>1036</fpage>&#x02013;<lpage>1047</lpage><pub-id pub-id-type="pmid">16160707</pub-id></citation></ref><ref id="R14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evenden</surname><given-names>JL</given-names></name></person-group> (<year>1999a</year>) <article-title>The pharmacology of                        impulsive behaviour in rats V: the effects of drugs on responding under a                        discrimination task using unreliable visual stimuli.</article-title><source>Psychopharmacology</source><volume>143</volume>:                <fpage>111</fpage>&#x02013;<lpage>122</lpage><pub-id pub-id-type="pmid">10326773</pub-id></citation></ref><ref id="R15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evenden</surname><given-names>JL</given-names></name></person-group> (<year>1999b</year>) <article-title>Varieties of impulsivity.</article-title><source>Psychopharmacology</source><volume>146</volume>:                <fpage>348</fpage>&#x02013;<lpage>361</lpage><pub-id pub-id-type="pmid">10550486</pub-id></citation></ref><ref id="R16"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Eysenck</surname><given-names>HJ</given-names></name><name><surname>Eysenck</surname><given-names>SB</given-names></name></person-group> (<year>1991</year>) <source>The Impulsiveness (IVE)                        Questionnaire.</source><publisher-loc>Kent, UK</publisher-loc>: <publisher-name>Hodder &#x00026;                        Stoughton</publisher-name></citation></ref><ref id="R17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Field</surname><given-names>M</given-names></name><name><surname>Santarcangelo</surname><given-names>M</given-names></name><name><surname>Sumnall</surname><given-names>H</given-names></name><name><surname>Goudie</surname><given-names>A</given-names></name><name><surname>Cole</surname><given-names>J</given-names></name></person-group> (<year>2006</year>) <article-title>Delay discounting and the                        behavioural economics of cigarette purchases in smokers: the effects of                        nicotine deprivation.</article-title><source>Psychopharmacology (Berl)</source><volume>186</volume>:                <fpage>255</fpage>&#x02013;<lpage>263</lpage><pub-id pub-id-type="pmid">16609902</pub-id></citation></ref><ref id="R18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fillmore</surname><given-names>MT</given-names></name><name><surname>Rush</surname><given-names>CR</given-names></name></person-group> (<year>2002</year>) <article-title>Impaired inhibitory control                        of behavior in chronic cocaine users.</article-title><source>Drug Alcohol Depend</source><volume>66</volume>:                <fpage>265</fpage>&#x02013;<lpage>273</lpage><pub-id pub-id-type="pmid">12062461</pub-id></citation></ref><ref id="R19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Forman</surname><given-names>SD</given-names></name><name><surname>Dougherty</surname><given-names>GG</given-names></name><name><surname>Casey</surname><given-names>BJ</given-names></name><name><surname>Siegle</surname><given-names>GJ</given-names></name><name><surname>Braver</surname><given-names>TS</given-names></name><name><surname>Barch</surname><given-names>DM</given-names></name><name><surname>Stenger</surname><given-names>VA</given-names></name><name><surname>Wick-Hull</surname><given-names>C</given-names></name><name><surname>Pisarov</surname><given-names>LA</given-names></name><name><surname>Lorensen</surname><given-names>E</given-names></name></person-group> (<year>2004</year>) <article-title>Opiate addicts lack                        error-dependent activation of rostral anterior cingulate.</article-title><source>Biol Psychiatry</source><volume>55</volume>:                <fpage>531</fpage>&#x02013;<lpage>537</lpage><pub-id pub-id-type="pmid">15023582</pub-id></citation></ref><ref id="R20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>HC</given-names></name><name><surname>McLean</surname><given-names>A</given-names></name><name><surname>Turner</surname><given-names>JJ</given-names></name><name><surname>Parrott</surname><given-names>AC</given-names></name><name><surname>Rogers</surname><given-names>R</given-names></name><name><surname>Sahakian</surname><given-names>BJ</given-names></name></person-group> (<year>2002</year>) <article-title>Neuropsychological evidence                        of a relatively selective profile of temporal dysfunction in drug-free MDMA                        ("ecstasy") polydrug users.</article-title><source>Psychopharmacology</source><volume>162</volume>:                <fpage>203</fpage>&#x02013;<lpage>214</lpage><pub-id pub-id-type="pmid">12110998</pub-id></citation></ref><ref id="R21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giordano</surname><given-names>LA</given-names></name><name><surname>Bickel</surname><given-names>WK</given-names></name><name><surname>Loewenstein</surname><given-names>G</given-names></name><name><surname>Jacobs</surname><given-names>EA</given-names></name><name><surname>Marsch</surname><given-names>L</given-names></name><name><surname>Badger</surname><given-names>GJ</given-names></name></person-group> (<year>2002</year>) <article-title>Mild opioid deprivation                        increases the degree that opioid-dependent outpatients discount delayed                        heroin and money.</article-title><source>Psychopharmacology (Berl)</source><volume>163</volume>:                <fpage>174</fpage>&#x02013;<lpage>182</lpage><pub-id pub-id-type="pmid">12202964</pub-id></citation></ref><ref id="R22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>RZ</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name></person-group> (<year>2002</year>) <article-title>Drug addiction and its                        underlying neurobiological basis: neuroimaging evidence for the involvement                        of the frontal cortex.</article-title><source>Am J Psychiatry</source><volume>159</volume>:                <fpage>1642</fpage>&#x02013;<lpage>1652</lpage><pub-id pub-id-type="pmid">12359667</pub-id></citation></ref><ref id="R23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gouzoulis-Mayfrank</surname><given-names>E</given-names></name><name><surname>Daumann</surname><given-names>J</given-names></name></person-group> (<year>2006</year>) <article-title>Neurotoxicity of                        methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the                        evidence for persistent brain damage?</article-title><source>Addiction</source><volume>101</volume>:                <fpage>348</fpage>&#x02013;<lpage>361</lpage><pub-id pub-id-type="pmid">16499508</pub-id></citation></ref><ref id="R24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gouzoulis-Mayfrank</surname><given-names>E</given-names></name><name><surname>Thimm</surname><given-names>B</given-names></name><name><surname>Rezk</surname><given-names>M</given-names></name><name><surname>Hensen</surname><given-names>G</given-names></name><name><surname>Daumann</surname><given-names>J</given-names></name></person-group> (<year>2003</year>) <article-title>Memory impairment suggests                        hippocampal dysfunction in abstinent ecstasy users.</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><volume>27</volume>:                <fpage>819</fpage>&#x02013;<lpage>827</lpage><pub-id pub-id-type="pmid">12921915</pub-id></citation></ref><ref id="R25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halpern</surname><given-names>JH</given-names></name><name><surname>Pope</surname><given-names>HG</given-names><suffix>Jr</suffix></name><name><surname>Sherwood</surname><given-names>AR</given-names></name><name><surname>Barry</surname><given-names>S</given-names></name><name><surname>Hudson</surname><given-names>JI</given-names></name><name><surname>Yurgelun-Todd</surname><given-names>D</given-names></name></person-group> (<year>2004</year>) <article-title>Residual neuropsychological                        effects of illicit 3,4-methylenedioxymethamphetamine (MDMA) in individuals                        with minimal exposure to other drugs.</article-title><source>Drug Alcohol Depend</source><volume>75</volume>:                <fpage>135</fpage>&#x02013;<lpage>147</lpage><pub-id pub-id-type="pmid">15276218</pub-id></citation></ref><ref id="R26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jentsch</surname><given-names>JD</given-names></name><name><surname>Taylor</surname><given-names>JR</given-names></name></person-group> (<year>1999</year>) <article-title>Impulsivity resulting from                        frontostriatal dysfunction in drug abuse: implications for the control of                        behavior by reward-related stimuli.</article-title><source>Psychopharmacology (Berl)</source><volume>146</volume>:                <fpage>373</fpage>&#x02013;<lpage>390</lpage><pub-id pub-id-type="pmid">10550488</pub-id></citation></ref><ref id="R27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kagan</surname><given-names>J</given-names></name></person-group> (<year>1966</year>) <article-title>Reflection-impulsivity: the                        generality and dynamics of conceptual tempo.</article-title><source>J Abnorm Psychol</source><volume>71</volume>: <fpage>17</fpage>&#x02013;<lpage>24</lpage><pub-id pub-id-type="pmid">5902550</pub-id></citation></ref><ref id="R28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>LeMarquand</surname><given-names>DG</given-names></name><name><surname>Benkelfat</surname><given-names>C</given-names></name><name><surname>Pihl</surname><given-names>RO</given-names></name><name><surname>Palmour</surname><given-names>RM</given-names></name><name><surname>Young</surname><given-names>SN</given-names></name></person-group> (<year>1999</year>) <article-title>Behavioral disinhibition                        induced by tryptophan depletion in nonalcoholic young men with                        multigenerational family histories of paternal alcoholism.</article-title><source>Am J Psychiatry</source><volume>156</volume>:                <fpage>1771</fpage>&#x02013;<lpage>1779</lpage><pub-id pub-id-type="pmid">10553742</pub-id></citation></ref><ref id="R29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lijffijt</surname><given-names>M</given-names></name><name><surname>Bekker</surname><given-names>EM</given-names></name><name><surname>Quik</surname><given-names>EH</given-names></name><name><surname>Bakker</surname><given-names>J</given-names></name><name><surname>Kenemans</surname><given-names>JL</given-names></name><name><surname>Verbaten</surname><given-names>MN</given-names></name></person-group> (<year>2004</year>) <article-title>Differences between low and                        high trait impulsivity are not associated with differences in inhibitory                        motor control.</article-title><source>J Atten Disord</source><volume>8</volume>: <fpage>25</fpage>&#x02013;<lpage>32</lpage><pub-id pub-id-type="pmid">15669600</pub-id></citation></ref><ref id="R30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linnoila</surname><given-names>M</given-names></name><name><surname>Virkkunen</surname><given-names>M</given-names></name><name><surname>Scheinin</surname><given-names>M</given-names></name><name><surname>Nuutila</surname><given-names>A</given-names></name><name><surname>Rimon</surname><given-names>R</given-names></name><name><surname>Goodwin</surname><given-names>FK</given-names></name></person-group> (<year>1983</year>) <article-title>Low cerebrospinal fluid                        5-hydroxyindoleacetic acid concentration differentiates impulsive from                        nonimpulsive violent behavior.</article-title><source>Life Sci</source><volume>33</volume>:                <fpage>2609</fpage>&#x02013;<lpage>2614</lpage><pub-id pub-id-type="pmid">6198573</pub-id></citation></ref><ref id="R31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lyvers</surname><given-names>M</given-names></name></person-group> (<year>2000</year>) &#x0201c;<article-title>Loss of                        control&#x0201d; in alcoholism and drug addiction: a neuroscientific                        interpretation.</article-title><source>Exp Clin Psychopharmacol</source><volume>8</volume>: <fpage>225</fpage>&#x02013;<lpage>249</lpage><pub-id pub-id-type="pmid">10843306</pub-id></citation></ref><ref id="R32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lyvers</surname><given-names>M</given-names></name></person-group> (<year>2006</year>) <article-title>Recreational ecstasy use and                        the neurotoxic potential of MDMA: current status of the controversy and                        methodological issues.</article-title><source>Drug Alcohol Rev</source><volume>25</volume>:                <fpage>269</fpage>&#x02013;<lpage>276</lpage><pub-id pub-id-type="pmid">16753651</pub-id></citation></ref><ref id="R33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lyvers</surname><given-names>M</given-names></name><name><surname>Hasking</surname><given-names>P</given-names></name></person-group> (<year>2004</year>) Have Halpern, <italic>et al.</italic> (2004)                    detected &#x02018;residual neuropsychological effects&#x02019; of MDMA?                    Not likely. <source>Drug Alcohol Depend</source><volume>75</volume>: <fpage>149</fpage>&#x02013;<lpage>152</lpage>;                        <comment>discussion 153</comment><pub-id pub-id-type="pmid">15276219</pub-id></citation></ref><ref id="R34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCann</surname><given-names>UD</given-names></name><name><surname>Ridenour</surname><given-names>A</given-names></name><name><surname>Shaham</surname><given-names>Y</given-names></name><name><surname>Ricaurte</surname><given-names>GA</given-names></name></person-group> (<year>1994</year>) <article-title>Serotonin neurotoxicity after                        (+/-)3,4-methylenedioxymethamphetamine (MDMA;                        &#x0201c;Ecstasy&#x0201d;): a controlled study in humans.</article-title><source>Neuropsychopharmacology</source><volume>10</volume>:                <fpage>129</fpage>&#x02013;<lpage>138</lpage><pub-id pub-id-type="pmid">7517677</pub-id></citation></ref><ref id="R35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moeller</surname><given-names>FG</given-names></name><name><surname>Dougherty</surname><given-names>DM</given-names></name><name><surname>Barratt</surname><given-names>ES</given-names></name><name><surname>Oderinde</surname><given-names>V</given-names></name><name><surname>Mathias</surname><given-names>CW</given-names></name><name><surname>Harper</surname><given-names>RA</given-names></name><name><surname>Swann</surname><given-names>AC</given-names></name></person-group> (<year>2002a</year>) <article-title>Increased impulsivity in                        cocaine dependent subjects independent of antisocial personality disorder                        and aggression.</article-title><source>Drug Alcohol Depend</source><volume>68</volume>:                <fpage>105</fpage>&#x02013;<lpage>111</lpage><pub-id pub-id-type="pmid">12167556</pub-id></citation></ref><ref id="R36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moeller</surname><given-names>FG</given-names></name><name><surname>Dougherty</surname><given-names>DM</given-names></name><name><surname>Steinberg</surname><given-names>JL</given-names></name><name><surname>Swann</surname><given-names>AC</given-names></name><name><surname>Silverman</surname><given-names>PB</given-names></name><name><surname>Ruiz</surname><given-names>P</given-names></name><name><surname>Barratt</surname><given-names>ES</given-names></name></person-group> (<year>2002b</year>) <article-title>Heavy                        &#x0201c;Ecstasy&#x0201d; use is associated with increased                        impulsivity.</article-title><source>Addict Dis Treat</source><volume>1</volume>: <fpage>47</fpage>&#x02013;<lpage>52</lpage></citation></ref><ref id="R37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>MJ</given-names></name></person-group> (<year>1998</year>) <article-title>Recreational use of "ecstasy"                        (MDMA) is associated with elevated impulsivity.</article-title><source>Neuropsychopharmacology</source><volume>19</volume>:                <fpage>252</fpage>&#x02013;<lpage>264</lpage><pub-id pub-id-type="pmid">9718589</pub-id></citation></ref><ref id="R38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>MJ</given-names></name><name><surname>Impallomeni</surname><given-names>LC</given-names></name><name><surname>Pirona</surname><given-names>A</given-names></name><name><surname>Rogers</surname><given-names>RD</given-names></name></person-group> (<year>2006</year>) <article-title>Elevated impulsivity and                        impaired decision-making in abstinent Ecstasy (MDMA) users compared to                        polydrug and drug-naive controls.</article-title><source>Neuropsychopharmacology</source><volume>31</volume>:                <fpage>1562</fpage>&#x02013;<lpage>1573</lpage><pub-id pub-id-type="pmid">16292322</pub-id></citation></ref><ref id="R39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>MJ</given-names></name><name><surname>McFie</surname><given-names>L</given-names></name><name><surname>Fleetwood</surname><given-names>H</given-names></name><name><surname>Robinson</surname><given-names>JA</given-names></name></person-group> (<year>2002</year>) <article-title>Ecstasy (MDMA): are the                        psychological problems associated with its use reversed by prolonged                        abstinence?</article-title><source>Psychopharmacology</source><volume>159</volume>:                <fpage>294</fpage>&#x02013;<lpage>303</lpage><pub-id pub-id-type="pmid">11862362</pub-id></citation></ref><ref id="R40"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>HE</given-names></name><name><surname>Willison</surname><given-names>J</given-names></name></person-group> (<year>1991</year>) <source>National Adult Reading Test (NART)                        Test Manual.</source><publisher-loc>Windsor, UK</publisher-loc>:                    <publisher-name>NFER-Nelson</publisher-name></citation></ref><ref id="R41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nigg</surname><given-names>JT</given-names></name><name><surname>Wong</surname><given-names>MM</given-names></name><name><surname>Martel</surname><given-names>MM</given-names></name><name><surname>Jester</surname><given-names>JM</given-names></name><name><surname>Puttler</surname><given-names>LI</given-names></name><name><surname>Glass</surname><given-names>JM</given-names></name><name><surname>Adams</surname><given-names>KM</given-names></name><name><surname>Fitzgerald</surname><given-names>HE</given-names></name><name><surname>Zucker</surname><given-names>RA</given-names></name></person-group> (<year>2006</year>) <article-title>Poor response inhibition as a                        predictor of problem drinking and illicit drug use in adolescents at risk                        for alcoholism and other substance use disorders.</article-title><source>J Am Acad Child Adolesc Psychiatry</source><volume>45</volume>:                <fpage>468</fpage>&#x02013;<lpage>475</lpage><pub-id pub-id-type="pmid">16601652</pub-id></citation></ref><ref id="R42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parrott</surname><given-names>AC</given-names></name><name><surname>Sisk</surname><given-names>E</given-names></name><name><surname>Turner</surname><given-names>JJ</given-names></name></person-group> (<year>2000</year>) <article-title>Psychobiological problems in                        heavy &#x02018;ecstasy&#x02019; (MDMA) polydrug users.</article-title><source>Drug Alcohol Depend</source><volume>60</volume>:                <fpage>105</fpage>&#x02013;<lpage>110</lpage><pub-id pub-id-type="pmid">10821995</pub-id></citation></ref><ref id="R43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petry</surname><given-names>NM</given-names></name></person-group> (<year>2001</year>) <article-title>Delay discounting of money                        and alcohol in actively using alcoholics, currently abstinent alcoholics,                        and controls.</article-title><source>Psychopharmacology (Berl)</source><volume>154</volume>:                <fpage>243</fpage>&#x02013;<lpage>250</lpage><pub-id pub-id-type="pmid">11351931</pub-id></citation></ref><ref id="R44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quednow</surname><given-names>BB</given-names></name><name><surname>Kuhn</surname><given-names>KU</given-names></name><name><surname>Hoppe</surname><given-names>C</given-names></name><name><surname>Westheide</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>W</given-names></name><name><surname>Daum</surname><given-names>I</given-names></name><name><surname>Wagner</surname><given-names>M</given-names></name></person-group> (<year>2007</year>) <article-title>Elevated impulsivity and                        impaired decision-making cognition in heavy users of MDMA                        (&#x0201c;Ecstasy&#x0201d;).</article-title><source>Psychopharmacology (Berl)</source><volume>189</volume>:                <fpage>517</fpage>&#x02013;<lpage>530</lpage><pub-id pub-id-type="pmid">16425060</pub-id></citation></ref><ref id="R45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>B</given-names></name><name><surname>Ortengren</surname><given-names>A</given-names></name><name><surname>Richards</surname><given-names>JB</given-names></name><name><surname>de Wit</surname><given-names>H</given-names></name></person-group> (<year>2006</year>) <article-title>Dimensions of impulsive                        behavior: personality and behavioral measures.</article-title><source>Pers Individ Dif</source><volume>20</volume>:                <fpage>305</fpage>&#x02013;<lpage>315</lpage></citation></ref><ref id="R46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sher</surname><given-names>KJ</given-names></name><name><surname>Trull</surname><given-names>TJ</given-names></name></person-group> (<year>1994</year>) <article-title>Personality and disinhibitory                        psychopathology: alcoholism and antisocial personality disorder.</article-title><source>J Abnorm Psychol</source><volume>103</volume>:                <fpage>92</fpage>&#x02013;<lpage>102</lpage><pub-id pub-id-type="pmid">8040486</pub-id></citation></ref><ref id="R47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soubrie</surname><given-names>P</given-names></name></person-group> (<year>1986</year>) <article-title>Reconciling the role of                        central serotonin neurons in human and animal behaviour.</article-title><source>Behav Brain Res</source><volume>9</volume>: <fpage>319</fpage>&#x02013;<lpage>364</lpage></citation></ref><ref id="R48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stout</surname><given-names>JC</given-names></name><name><surname>Rock</surname><given-names>SL</given-names></name><name><surname>Campbell</surname><given-names>MC</given-names></name><name><surname>Busemeyer</surname><given-names>JR</given-names></name><name><surname>Finn</surname><given-names>PR</given-names></name></person-group> (<year>2005</year>) <article-title>Psychological processes                        underlying risky decisions in drug abusers.</article-title><source>Psychol Addict Behav</source><volume>19</volume>:                <fpage>148</fpage>&#x02013;<lpage>157</lpage><pub-id pub-id-type="pmid">16011385</pub-id></citation></ref><ref id="R49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tarter</surname><given-names>RE</given-names></name><name><surname>Kirisci</surname><given-names>L</given-names></name><name><surname>Habeych</surname><given-names>M</given-names></name><name><surname>Reynolds</surname><given-names>M</given-names></name><name><surname>Vanyukov</surname><given-names>M</given-names></name></person-group> (<year>2004</year>) <article-title>Neurobehavior disinhibition                        in childhood predisposes boys to substance use disorder by young adulthood:                        direct and mediated etiologic pathways.</article-title><source>Drug Alcohol Depend</source><volume>73</volume>:                <fpage>121</fpage>&#x02013;<lpage>132</lpage><pub-id pub-id-type="pmid">14725951</pub-id></citation></ref><ref id="R50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Travers</surname><given-names>KR</given-names></name><name><surname>Lyvers</surname><given-names>M</given-names></name></person-group> (<year>2005</year>) <article-title>Mood and impulsivity of                        recreational Ecstasy users in the week following a                        &#x0201c;rave&#x0201d;.</article-title><source>Addic Res Theory</source><volume>13</volume>: <fpage>43</fpage>&#x02013;<lpage>52</lpage></citation></ref><ref id="R51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tye</surname><given-names>NC</given-names></name><name><surname>Everitt</surname><given-names>BJ</given-names></name><name><surname>Iversen</surname><given-names>SD</given-names></name></person-group> (<year>1977</year>) <article-title>5-Hydroxytryptamine and                        punishment.</article-title><source>Nature</source><volume>268</volume>:                <fpage>741</fpage>&#x02013;<lpage>743</lpage><pub-id pub-id-type="pmid">895875</pub-id></citation></ref><ref id="R52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>von Geusau</surname><given-names>NA</given-names></name><name><surname>Stalenhoef</surname><given-names>P</given-names></name><name><surname>Huizinga</surname><given-names>M</given-names></name><name><surname>Snel</surname><given-names>J</given-names></name><name><surname>Ridderinkhof</surname><given-names>KR</given-names></name></person-group> (<year>2004</year>) <article-title>Impaired executive function                        in male MDMA (&#x0201c;ecstasy&#x0201d;) users.</article-title><source>Psychopharmacology (Berl)</source><volume>175</volume>:                <fpage>331</fpage>&#x02013;<lpage>341</lpage><pub-id pub-id-type="pmid">15034712</pub-id></citation></ref><ref id="R53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wareing</surname><given-names>M</given-names></name><name><surname>Fisk</surname><given-names>JE</given-names></name><name><surname>Murphy</surname><given-names>P</given-names></name><name><surname>Montgomery</surname><given-names>C</given-names></name></person-group> (<year>2005</year>) <article-title>Visuo-spatial working memory                        deficits in current and former users of MDMA                        (&#x02018;ecstasy&#x02019;).</article-title><source>Hum Psychopharmacol</source><volume>20</volume>:                <fpage>115</fpage>&#x02013;<lpage>123</lpage><pub-id pub-id-type="pmid">15641126</pub-id></citation></ref><ref id="R54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whitlow</surname><given-names>CT</given-names></name><name><surname>Liguori</surname><given-names>A</given-names></name><name><surname>Livengood</surname><given-names>LB</given-names></name><name><surname>Hart</surname><given-names>SL</given-names></name><name><surname>Mussat-Whitlow</surname><given-names>BJ</given-names></name><name><surname>Lamborn</surname><given-names>CM</given-names></name><name><surname>Laurienti</surname><given-names>PJ</given-names></name><name><surname>Porrino</surname><given-names>LJ</given-names></name></person-group> (<year>2004</year>) <article-title>Long-term heavy marijuana                        users make costly decisions on a gambling task.</article-title><source>Drug Alcohol Depend</source><volume>76</volume>:                <fpage>107</fpage>&#x02013;<lpage>111</lpage><pub-id pub-id-type="pmid">15380295</pub-id></citation></ref></ref-list></back></article>